Evidence map›Paper›PMID 41307761›Full record

ArticleBiomolecular NMR assignments2025

NMR assignments of the human homodimeric mitochondrial ATP synthase inhibitor IF1.

Julia Jerolamon, Nathan N Alder, Andrei T Alexandrescu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecular NMR assignments, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. High-pH NMR to Identify Macromolecular Hydrogen-Bonds and Foldons.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Julia JerolamonDepartment of Molecular and Cell Biology, University of Connecticut, 91 N. Eagleville Road, Storrs, CT, 06269-3125, USA.ORCID http://orcid.org/0009-0001-5159-5310
Nathan N AlderDepartment of Molecular and Cell Biology, University of Connecticut, 91 N. Eagleville Road, Storrs, CT, 06269-3125, USA. nathan.alder@uconn.edu.ORCID http://orcid.org/0000-0003-4474-7803
Andrei T AlexandrescuDepartment of Molecular and Cell Biology, University of Connecticut, 91 N. Eagleville Road, Storrs, CT, 06269-3125, USA. andrei.alexandrescu@uconn.edu.ORCID http://orcid.org/0000-0002-8425-9276

Funding

First-in-class peptide therapeutics for mitochondrial disorders: molecular mechanism of action and optimization of designR01AG065879 · NIA · UNIVERSITY OF CONNECTICUT STORRS · PI ALDER, NATHAN N · 2020 to 2024
$2.6M
NIA NIH HHS R01 AG065879NIH HHS R01-AG065879
6 · The paper itself

Abstract

ATPase inhibitory factor 1 (IF1) is the only known endogenous, proteinaceous inhibitor of mitochondrial ATP synthase in mammals. The inhibitor forms an antiparallel coiled-coil, which binds ATP synthase through an N-terminal α-helix extension that is disordered in the free protein. Because the IF1 dimer affects mitochondrial bioenergetics through its modulation of ATP synthase, it is a therapeutic target for cancer and cardiac disease. Here, we report

Indexed as

Enzyme InhibitorsMitochondrial Proton-Translocating ATPasesNuclear Magnetic Resonance, BiomolecularProtein MultimerizationATPase Inhibitory ProteinHumansATPase Inhibitory ProteinEnzyme InhibitorsMitochondrial Proton-Translocating ATPasesATPase inhibitorATP synthaseCoiled-coil dimerMitochondriaPH-dependent oligomer

Identifiers

PMID41307761
PMCPMC13067138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.